Analyst Expectations for Intra-Cellular Therapies's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on Intra-Cellular Therapies (NASDAQ:ITCI) stock, with an average price target of $75.71, an increase of 1.76% from the previous average price target of $74.40. The majority of the ratings are bullish.
August 04, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Intra-Cellular Therapies (NASDAQ:ITCI) with an average price target of $75.71, indicating potential upside.
The bullish outlook from analysts indicates a positive sentiment towards the stock. The increase in the average price target suggests that analysts believe the stock has potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100